# Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

> **NCT00289640** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 210 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** ipilimumab (MDX-010, BMS-734016)
- **DRUG:** Ipilimumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT00289640
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2010-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00289640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00289640, "Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00289640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*